Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Meets Estimates

Curis (NASDAQ:CRISGet Rating) issued its earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17), RTT News reports. Curis had a negative net margin of 533.89% and a negative return on equity of 63.12%. During the same quarter in the previous year, the firm earned ($0.12) earnings per share.

Curis Price Performance

CRIS traded up $0.01 on Friday, reaching $1.00. 3,597,175 shares of the company’s stock were exchanged, compared to its average volume of 1,529,752. The stock has a market cap of $91.64 million, a PE ratio of -1.61 and a beta of 2.66. Curis has a twelve month low of $0.70 and a twelve month high of $9.04. The stock’s fifty day moving average price is $1.03 and its 200-day moving average price is $1.78.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, May 12th.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its holdings in Curis by 465.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 446,469 shares of the biotechnology company’s stock valued at $1,063,000 after purchasing an additional 367,559 shares during the last quarter. Walleye Capital LLC raised its stake in shares of Curis by 3,036.1% in the 1st quarter. Walleye Capital LLC now owns 841,793 shares of the biotechnology company’s stock valued at $2,003,000 after acquiring an additional 814,951 shares during the period. Dynamic Technology Lab Private Ltd raised its stake in shares of Curis by 40.2% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 40,700 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 11,660 shares during the period. PDT Partners LLC purchased a new stake in shares of Curis in the 1st quarter valued at approximately $150,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Curis in the 1st quarter valued at approximately $32,000. 78.15% of the stock is currently owned by institutional investors and hedge funds.

About Curis

(Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Featured Articles

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.